2 weeks Ago By Defense World Staff
Shares of Edwards Lifesciences Co. (NYSE:EW – Get Free Report) have earned a consensus rating of “Hold” from the twenty-four analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have given a buy rating to the company.
The average twelve-month price target among brokers that have covered the stock in the last year is $78.55. EW has been the topic of several recent analyst reports.
Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th.
Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th.
Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th.
Finally, Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th.
View Our Latest Analysis on EWEdwards Lifesciences Trading Up 0.5 %Shares of EW stock opened at $71.56 on Friday.
Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $95.25.
The company has a market cap of $42.07 billion, a PE ratio of 10.27, a price-to-earnings-growth ratio of 4.
82 and a beta of 1.15. The company has a quick ratio of 2.
89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.
The business’s 50 day moving average is $71.31 and its two-hundred day moving average is $70.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.
55 by $0.04. Edwards Lifesciences had a net margin of 72.
93% and a return on equity of 19.40%. Equities analysts predict that Edwards Lifesciences will post 2.
45 EPS for the current year. Insider Buying and SellingIn related news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction on Thursday, February 13th.
The stock was sold at an average price of $75.76, for a total transaction of $852,300.00.
Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This trade represents a 26.
91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steven R.
Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.
38. Following the completion of the transaction, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24.
This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here.
Insiders sold 71,853 shares of company stock worth $5,163,062 in the last quarter. 1.29% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Edwards LifesciencesHedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. raised its position in Edwards Lifesciences by 2.
5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after purchasing an additional 273 shares during the last quarter.
Nordea Investment Management AB raised its position in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares during the last quarter.
WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after acquiring an additional 300,000 shares during the period.
Sivik Global Healthcare LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at about $3,702,000. Finally, Avanza Fonder AB acquired a new stake in Edwards Lifesciences in the fourth quarter worth about $4,845,000. Institutional investors and hedge funds own 79.
46% of the company’s stock. Edwards Lifesciences Company Profile (Get Free ReportEdwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured StoriesFive stocks we like better than Edwards LifesciencesWhat is a Secondary Public Offering? What Investors Need to Know3 Mid-Cap to Mega-Cap Stocks Have Announced Significant BuybacksHow to Invest in Insurance Companies: A Guide These 3 Stocks Have Huge Last 12 Months Shareholder Yields3 Warren Buffett Stocks to Buy NowProminent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?.
